Midazolam nasal spray exempted from price control for 5 years
NPPA order S.O. 6000(E) of November 2, 2026 exempts Biodeal Pharmaceuticals' Midazolam Nasal Spray 1.25 mg from the DPCO, 2013 for five years from May 5, 2025. It applies to M/s. Biodeal Pharmaceuticals Limited, for "Midazolam Nasal Spray 1.25 mg".
The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals of the Ministry of Chemicals and Fertilizers, issued Order S.O. 6000(E) dated November 2, 2026, published the same day in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section (ii), No. 5768. It uses the power in paragraph 32 of the Drugs (Prices Control) Order, 2013 (DPCO, 2013), delegated to NPPA by S.O. 1394(E) of May 30, 2013 under sections 3 and 5 of the Essential Commodities Act, 1955.
M/s. Biodeal Pharmaceuticals Limited applied for exemption under paragraph 32(iii) for "Midazolam Nasal Spray 1.25 mg", which the Central Drugs Standard Control Organization (CDSCO) approved as a new drug under the Drugs and Cosmetics Act, 1940 and its rules. At its 153rd meeting, held on October 29, 2026, NPPA considered the recommendations of the Multidisciplinary Committee (MDC) and approved the exemption.
The order exempts the company from the provisions of the DPCO, 2013 for this formulation for five years with effect from May 5, 2025, the date CDSCO granted marketing approval. The company must tell NPPA the Price to Retailer (PTR) and Maximum Retail Price (MRP) it fixes, by issuing a price list in Form V. Three months before the exemption ends, it must follow the ceiling price or seek retail price approval for the formulation, as applicable.
The order does not state the PTR or MRP, the date by which the Form V price list is due, or why the formulation qualifies under paragraph 32(iii). It covers only this formulation of this company. It is signed by Bhiva Ram Yadav, Assistant Director, under PN/285/153/2026/F/F. No. 8(153)/2026/D.P./NPPA-Div.-II.
- Issued by
- National Pharmaceutical Pricing Authority (NPPA), Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers
- Document
- Order S.O. 6000(E), under paragraph 32 of the Drugs (Prices Control) Order, 2013
- Dated
- November 2, 2026
- Published
- Gazette of India, Extraordinary, Part II, Section 3, Sub-section (ii), No. 5768, November 2, 2026
- Applies to
- M/s. Biodeal Pharmaceuticals Limited, for "Midazolam Nasal Spray 1.25 mg"
- Exemption
- From the provisions of the DPCO, 2013, under paragraph 32(iii)
- Period
- Five years with effect from May 5, 2025, the date of CDSCO's marketing approval
- Decided at
- NPPA's 153rd meeting, October 29, 2026, on the Multidisciplinary Committee's recommendations
- Price list
- PTR and MRP to NPPA in Form V
- Before the exemption ends
- Follow the ceiling price or seek retail price approval, as applicable, three months before expiry
- Signed by
- Bhiva Ram Yadav, Assistant Director
The order (PDF, 619 KB)
Source: Gazette of India, CG-DL-E-03112026-277621.
Checked against the official copy on November 7, 2026.